179 related articles for article (PubMed ID: 37542037)
1. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer.
Zhou Q; Peng Y; Ji F; Chen H; Kang W; Chan LS; Gou H; Lin Y; Huang P; Chen D; Wei Q; Su H; Liang C; Zhang X; Yu J; Wong CC
Nat Commun; 2023 Aug; 14(1):4677. PubMed ID: 37542037
[TBL] [Abstract][Full Text] [Related]
2. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
3. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
4. METTL3 Inhibits Antitumor Immunity by Targeting m
Chen H; Pan Y; Zhou Q; Liang C; Wong CC; Zhou Y; Huang D; Liu W; Zhai J; Gou H; Su H; Zhang X; Xu H; Wang Y; Kang W; Kei Wu WK; Yu J
Gastroenterology; 2022 Oct; 163(4):891-907. PubMed ID: 35700773
[TBL] [Abstract][Full Text] [Related]
5. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
8. LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in
Li X; Chung ACK; Li S; Wu L; Xu J; Yu J; Wong C; Cai Z
Oncotarget; 2017 Nov; 8(60):101333-101344. PubMed ID: 29254168
[TBL] [Abstract][Full Text] [Related]
9. Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer.
Liu H; Liang Z; Cheng S; Huang L; Li W; Zhou C; Zheng X; Li S; Zeng Z; Kang L
Adv Sci (Weinh); 2023 Feb; 10(6):e2203757. PubMed ID: 36599679
[TBL] [Abstract][Full Text] [Related]
10. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.
Zhai J; Chen H; Wong CC; Peng Y; Gou H; Zhang J; Pan Y; Chen D; Lin Y; Wang S; Kang W; To KF; Chen Z; Nie Y; He HH; Sung JJ; Yu J
Gastroenterology; 2023 Aug; 165(2):445-462. PubMed ID: 37169182
[TBL] [Abstract][Full Text] [Related]
11. Targeting m
Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
[TBL] [Abstract][Full Text] [Related]
12. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
13. DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.
Hu J; Wang Z; Chen Z; Li A; Sun J; Zheng M; Wu J; Shen T; Qiao J; Li L; Li B; Wu D; Xiao Q
Biomed Pharmacother; 2020 Jul; 127():110229. PubMed ID: 32559853
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
15. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
[TBL] [Abstract][Full Text] [Related]
16. SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis.
Hu SS; Han Y; Tan TY; Chen H; Gao JW; Wang L; Yang MH; Zhao L; Wang YQ; Ding YQ; Wang S
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937641
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
[TBL] [Abstract][Full Text] [Related]
18. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer.
Wong CC; Wu JL; Ji F; Kang W; Bian X; Chen H; Chan LS; Luk STY; Tong S; Xu J; Zhou Q; Liu D; Su H; Gou H; Cheung AH; To KF; Cai Z; Shay JW; Yu J
Nat Commun; 2022 Jul; 13(1):3971. PubMed ID: 35803966
[TBL] [Abstract][Full Text] [Related]
19. Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis.
Domvri K; Petanidis S; Zarogoulidis P; Anestakis D; Tsavlis D; Bai C; Huang H; Freitag L; Hohenforst-Schmidt W; Porpodis K; Katopodi T
Clin Immunol; 2021 Jan; 222():108620. PubMed ID: 33176208
[TBL] [Abstract][Full Text] [Related]
20. Targeting the ERβ/HER Oncogenic Network in
Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
